1 Schmidt W, "Role of carrier ligand in platinum resistance of human carcinoma cell lines" 53 : 799-805, 1993
2 Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer" 8 : 163-168, 1997
3 Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie" 26 : 1435-1442, 2008
4 Al-Batran SE, "Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer" 22 : 658-663, 2004
5 Lordick F, "Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer" 93 : 190-194, 2005
6 Chao Y, "Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer" 91 : 453-458, 2004
7 Louvet C, "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients" 20 : 4543-4548, 2002
8 Kim DY, "Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer" 14 : 383-387, 2003
9 Extra JM, "Phase I study of oxaliplatin in patients with advanced cancer" 25 : 299-303, 1990
10 Extra JM, "Pharmacokinetics and safety profile of oxaliplatin" 25 (25): 13-22, 1998
1 Schmidt W, "Role of carrier ligand in platinum resistance of human carcinoma cell lines" 53 : 799-805, 1993
2 Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer" 8 : 163-168, 1997
3 Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie" 26 : 1435-1442, 2008
4 Al-Batran SE, "Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer" 22 : 658-663, 2004
5 Lordick F, "Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer" 93 : 190-194, 2005
6 Chao Y, "Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer" 91 : 453-458, 2004
7 Louvet C, "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients" 20 : 4543-4548, 2002
8 Kim DY, "Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer" 14 : 383-387, 2003
9 Extra JM, "Phase I study of oxaliplatin in patients with advanced cancer" 25 : 299-303, 1990
10 Extra JM, "Pharmacokinetics and safety profile of oxaliplatin" 25 (25): 13-22, 1998
11 Woynarowski JM, "Oxaliplatin-induced damage of cellular DNA" 58 : 920-927, 2000
12 In Sil Choi, "Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer" 대한암학회 39 (39): 99-103, 2007
13 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 : 205-216, 2000
14 Waters JS, "Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial" 80 : 269-272, 1999
15 Vanhoefer U, "Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group" 18 : 2648-2657, 2000
16 Mamenta EL, "Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines" 54 : 3500-3505, 1994
17 Ohtsu A, "Chemotherapy for metastatic gastric cancer: past, present, and future" 43 : 256-264, 2008
18 Arnould S, "Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines" 39 : 112-119, 2003
19 Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer" 358 : 36-46, 2008
20 Pisters PW, "Cancer of the stomach, in Cancer: principles and practice of oncology" Lippincott Williams & Wilkins 909-944, 2005
21 Ravaioli A, "Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer" 20 : 2545-2550, 2002
22 Marchetti P, "Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line" 24 : 219-226, 2004